GLP-1s are an approved treatment for those with a BMI over 30, or a BMI over 27 with at least one comorbidity like type 2 diabetes, hypertension or sleep apnea
Tirzepatide is a synthetic peptide drug approved through the New Drug Application (NDA) pathway, not a biologic
Significant weight regain was observed in both subgroups (WMD = 1.45 kg, 95% CI 0.62 to 2.28, P = 0.006, I 2 = 72%
Both GLP1 and GIP act indirectly on white adipose tissue, whereas GIP directly regulates fat and amino acid metabolism and inflammation within brown adipose tissue
Injections tend to cost more upfront due to higher doses, supplies, and sometimes provider involvement
They are the same molecule presented under different names for different regulatory and marketing purposes